Pharmafile Logo
Pharmafocus logo
Advanced Search
jane_osbourn_lg

Dr Jane Osbourn to join BIA board as chair

October 28, 2015

Dr Jane Osbourn, the vice president of research and development at MedImmune, will be the new chair of the BIA …

Appointment
imlygic_amgen

FDA approves first-in-class Amgen melanoma drug

October 28, 2015
Research and Development, Sales and Marketing Amgen, Imlygic, melonoma

The US Food and Drug Administration (FDA) has approved Amgen’s Imlygic for the treatment of melanoma lesions in the skin …

News
Jinarc

Otsuka kidney drug earns first NICE nod

October 28, 2015
Research and Development, Sales and Marketing NHS, NICE, jinarc, kidney disease, tolvaptan

NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …

News
Merck image

Sales up at MSD while Keytruda hits survival target in late-stage trial

October 28, 2015
Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab

Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …

News
Sativex

Otsuka, GW announce Sativex fails in Phase III cancer pain trials

October 28, 2015
Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure

Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …

News
BGMA D-G Warwick Smith

OPINION: ‘More work remains if biosimilars are to fulfil their potential’

October 27, 2015
Manufacturing and Production, Research and Development, Sales and Marketing British Generic Manufacturers Association, NHS, bgma, biosimilars, generics, patent cliff, patents

Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in the UK, and as a …

Feature
George Freeman

Pharma reaction to the Government’s AAR review

October 27, 2015
Manufacturing and Production, Research and Development Accelerated Access Review

The long-awaited interim report on the Government’s Accelerated Access Review has been published.The Government department overseeing the report, the Office …

News
Shire image

New Phase III data puts Shire’s lifitegrast back on track for 2016 launch

October 27, 2015
Research and Development Shire, dry eye disease, lifitegrast

Shire shares rose 6% today as the company reported new positive Phase III trial data for lifitegrast in the treatment …

News
Europe flag

EMA launches scheme to prioritise medicines access for patients

October 27, 2015
Manufacturing and Production EMA, European Medicines Agency, medicines access

The EMA has launched a public consultation on a scheme which aims to enable access to more medicines.The PRIME scheme …

News
nhsa

North of England secures new ‘centres of excellence’ in ‘precision medicine’

October 27, 2015
Manufacturing and Production, Research and Development NHS, Northern Health Science Alliance, UK

The umbrella group formed by the leading northern universities, teaching hospitals and Academic Health Science Networks – the Northern Health …

News
Kadcyla

Roche under pressure to drop price of Kadcyla

October 27, 2015
Manufacturing and Production Cancer Drugs Fund, Kadcyla, Roche, breast cancer

The UK’s largest breast cancer charity has called for drug manufacturer Roche to drop the price of Kadcyla before it …

News

Revealed: recommendations from the Accelerated Access Review

October 27, 2015
Manufacturing and Production, Research and Development Accelarated Access Review, NHS

Ministers have been urged to introduce conditional approvals for innovative new drugs, and ‘radically new’ central agreements on drug pricing, …

News
novartissunlight_copy

Novartis misses Q3 forecast with $390m settlement payment, strong dollar

October 27, 2015
Manufacturing and Production, Sales and Marketing Alcon, Novartis, Sandoz

Novartis reported lower-than anticipated third quarter earnings on Tuesday, hit by the $390 million settlement it has agreed to pay …

News
j

Valeant CEO rejects fraud accusations in conference call

October 27, 2015
Manufacturing and Production, Medical Communications, Sales and Marketing

Valeant says it will establish a committee to review allegations about the company’s relationship with specialist pharmacy Philidor, following what …

News
gsk_hq

GSK’s Volibris gets pulmonary arterial hypertension approval in Europe

October 26, 2015
Research and Development, Sales and Marketing EMA, GSK

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …

News
imprimis_logo

Imprimis launches low-cost Daraprim alternative

October 26, 2015
Sales and Marketing Daraprim, Imprimis, Martin Skhreli, turing

Imprimis Pharmaceuticals has announced that it has made available a customisable compounded formulation of pyrimethamine and leucovorin accessible for physicians …

News
valeant_logo_on_board

CEO prepares for day of reckoning over Valeant fraud allegations

October 26, 2015
Sales and Marketing J. Michael Pearson, Valeant

Troubled Valeant Pharmaceuticals last week announced strong third quarter revenues, reporting a 36% increase in revenues to $172 million, but …

News
robert_langer

Puretech Health co-founder and board member Dr Robert Langer wins global engineering prize

October 26, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Dr Robert Langer, Engineering, PureTech Health, Queen Elizabeth engineering prize

Dr Robert Langer, the co-founder of PureTech Health, has won the Queen Elizabeth prize for engineering.The award is in recognition …

Appointment
AZ sign

FDA backs AZ gout drug despite safety concerns

October 26, 2015
Sales and Marketing AstraZeneca, Zurampic, gout, lesinurad

FDA reviewers have recommended approving AstraZeneca’s new gout therapy Zurampic, which the company purchased in a $1.3 billion buyout, despite …

News
shire_image_4

Shire reports 7% product sales growth, continues Baxalta pursuit

October 23, 2015
Sales and Marketing Baxalta, Shire

Shire has exceeded market expectations as it reported an 11% rise in Q3 earnings on Friday, driven by product sales, …

News
The Gateway to Local Adoption Series

Latest content

Campaign highlights low expectations among patients with depression

May 7, 2026

Practical AI toolkit launched to help manufacturers cut through complexity

May 6, 2026

Syngene appoints Maninder Kapoor Puri as CHRO

May 6, 2026

BioPhorum acquires PharmaX Solutions

May 5, 2026

Syngene appoints Abhijit Zutshi as CCO

May 5, 2026